Mr. Speaker, I would say quickly that one would be ISDS, which we have talked a fair bit about so far.
There were also a number of intellectual property provisions in CETA that are putting upward pressure on the cost of drugs, when Canadians already pay among the highest prices for prescription drugs in the world, so it does not make sense to be pursuing that. There is more to say about the WTO and TRIPS, vaccines and all that, but that is certainly part of it.
There are also some of the restrictions on the ability of local governments to make sure that the money they are investing actually goes to companies in their communities, so that that money stays and is part and parcel of building up local communities. America is doing that, despite our trade relationship. We are upset about that. We want access for our Canadian companies, but we are giving that away without reciprocity from our trading partners, and it does not make sense.
Canadian companies are not making tonnes of money on infrastructure projects in Europe, but European giants are here. In some cases they are sending their work forces here to take the work of Canadian trades people, for example, who could be doing that work. We need to consider these things when we are signing the agreement.